2018 Survivin-Targeted Immunotherapy Competitor Analysis – ResearchAndMarkets.com

Posted by on June 22, 2018 7:18 am
Tags:
Categories: Uncategorized

Source: 2018 Survivin-Targeted Immunotherapy Competitor Analysis – ResearchAndMarkets.com

DUBLIN–()–The “Competitor
Analysis: Survivin-Targeted Immunotherapy” report has been
added to ResearchAndMarkets.com’s offering.

This Competitive Intelligence report analyzes the competitive field of Survivin-Targeted
Immunotherapies as of May 2018 in a tabulated format with
structured listings of industry-relevant data.

The intracellular protein Survivin is the smallest member of the
Inhibitor of apoptosis (IAP) family of proteins, involved in inhibition
of apoptosis and regulation of cell cycle. These functional attributes
make Survivin an unique protein exhibiting divergent functions i.e.
regulating cell proliferation and cell death. Expression pattern of
Survivin is also distinctive; it is prominently expressed during
embryonal development, absent in most normal, terminally differentiated
tissues but upregulated in a variety of human cancers.

Expression of Survivin in tumours correlates with not only inhibition of
apoptosis and a decreased rate of cell death, but also resistance to
chemotherapy and aggressiveness of tumours. Therefore, Survivin is an
important target for cancer vaccines and cellular therapeutics. Survivin
peptide sequences have been used to develop vaccination strategies and
adoptive cell therapies.

The report includes a compilation of currently active projects in
research and development of active immunotherapy and adoptive cell
therapy targeting Survivin. In addition, the report lists company- and
institution-specific R&D pipelines of Survivin-Targeted
Immunotherapies.

Competitor projects are listed in a tabular format providing
information on:

  • Drug Codes
  • Target/Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of
    information.

Key Topics Covered:

1. Survivin-Targeted Immunotherapy

  • Survivin-Selective Cancer Vaccines
  • Survivin-Specific, Multi-Antigen Cancer Vaccines
  • Survivin-Selective Adoptive T-Cell Therapy & Oncolytic Viral
    Immunotherapy
  • Survivin-Specific, Multi-Target Adoptive T-Cell Therapy

2. Corporate Survivin Immunotherapy R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/9j6whl/2018?w=4

Published at Thu, 21 Jun 2018 20:00:55 +0000

< Immunotherapy Today home